Literature DB >> 32322918

Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening.

Guido Tavazzi1,2, Luca Civardi3, Luca Caneva3, Silvia Mongodi3, Francesco Mojoli4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32322918      PMCID: PMC7175449          DOI: 10.1007/s00134-020-06040-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear Editor, The COVID-19 outbreak in Wuhan city, China, in December 2019 has rapidly spread up to the level of Pandemia at the beginning of March 2020. A recent report from China has identified high inflammatory status as a predictor of adverse outcome, suggesting that mortality might be due to virally driven hyper-inflammation status [1]. There is a well-established link between inflammation and increased risk of deep vein thrombosis (DVT). A potential explanation is that vessel wall inflammation initiates thrombus formation, through the activation of endothelial cells, platelets, and leukocytes that trigger the coagulation pathway [2, 3]. Additionally, procoagulant state has long been recognized also as part of ARDS pathophysiology, demonstrated by the identification of diffuse pulmonary endothelial injury associated with platelets' activation, macro- and micro-thrombi thought to be either embolic, formed in situ or both [4]. Moreover, the interaction pathway among platelets, neutrophils, and endothelial cells' dysfunction in ARDS has been associated with deep vein thrombosis development [2]. High prevalence of acute pulmonary embolism (APE) has been recently reported in patients admitted with COVID-19-related pneumonia [5]. We report the prevalence of venous thrombotic events in patients consecutively admitted to the ICU of a Hub Hospital for SARS-CoV-2 since the beginning of the Italian outbreak infection on February 21, 2020. Informed consent was collected following the ad hoc procedures defined by the Ethics Committee for the COVID-19 pandemic. All patients were sedated, mechanically ventilated and treated with prophylactic low-molecular-weight heparin (LMWH) adjusted on body weight since the admission. Eight out of 54 patients (14.8%) were diagnosed with deep vein thrombosis, 6 of which were central catheter-related. Additionally, one patient had a thrombotic formation attached to the tricuspid valve in the absence of predisposing factors. Sub-segmental pulmonary embolism was found in two patients examined with computed tomography pulmonary angiography (CTPA) and one patient died of cardiac arrest with pulseless electrical activity (PEA) as presentation rhythm and sudden right ventricular dilatation. In our experience 22.2% of patients (83% male, 68 ± 7 years old; BMI 29.3 ± 4.4 kg/m2; C-reactive protein 25.7 ± 9.2 mg/dl, fibrinogen 657.1 ± 200.6 mg/dl) admitted to ICU due to SARS-CoV-2 interstitial pneumonia had venous thrombotic events (Fig. 1).
Fig. 1

Ultrasound demonstration of thrombotic events in patients admitted with SARS-Cov2. Deep vein ultrasound showing (a—ESM1) the internal jugular vein with a thrombus surrounding a central catheter (central white point) and (b—ESM2) a thrombus of superficial and common femoral vein (white asterisk). Transthoracic echocardiography subcostal view demonstrating (c—ESM3) a thrombus in the right ventricular cavity, attached to the tricuspid valve (white arrow) and (d—ESM4) parasternal short axis view in patient with right ventricular dilatation (right ventricular/left ventricular area 0.7) inducing interventricular paradoxical septal motion

Ultrasound demonstration of thrombotic events in patients admitted with SARS-Cov2. Deep vein ultrasound showing (a—ESM1) the internal jugular vein with a thrombus surrounding a central catheter (central white point) and (b—ESM2) a thrombus of superficial and common femoral vein (white asterisk). Transthoracic echocardiography subcostal view demonstrating (c—ESM3) a thrombus in the right ventricular cavity, attached to the tricuspid valve (white arrow) and (d—ESM4) parasternal short axis view in patient with right ventricular dilatation (right ventricular/left ventricular area 0.7) inducing interventricular paradoxical septal motion ICU admission and ARDS are considered both predisposing factors for a number of reasons, including the need for prolonged immobilization and hyper-inflammatory state. The prevalence of vein thrombosis in patients admitted with ARDS is currently unknown. A recent report showed that 10 out of 25 patients admitted with pneumonia due to COVID-19 presented sub-segmental APE, assessed with CPTA. No associated deep vein thrombosis was reported as the authors did not perform ultrasound screening. Because of the pathophysiological link between inflammation and thrombosis development [3], especially in critically ill patients, the hyper-inflammatory status of patients with COVID-19 [1] and the high prevalence of APE [5] and of vein thrombotic events found in our population, we strongly suggest that a close vein ultrasound screening and monitoring should be performed in all patients hospitalized due to SARS-CoV-2-related infection. Additionally, right ventricular dilatation/dysfunction should trigger the suspicion of APE. Below is the link to the electronic supplementary material. Supplementary material 1 (MOV 24576 kb) Supplementary material 2 (MOV 19509 kb) Supplementary material 3 (MOV 5325 kb) Supplementary material 4 (MOV 5320 kb)
  35 in total

Review 1.  Clinical Progress Note: Point-of-Care Ultrasound Applications in COVID-19.

Authors:  Benji K Mathews; Seth Koenig; Linda Kurian; Benjamin Galen; Gregory Mints; Gigi Liu; Nilam J Soni
Journal:  J Hosp Med       Date:  2020-06       Impact factor: 2.960

2.  Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies.

Authors:  Gaurav Agarwal; Adrija Hajra; Sandipan Chakraborty; Neelkumar Patel; Suman Biswas; Mark K Adler; Carl J Lavie
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec

3.  Comparative study of lung ultrasound and chest computed tomography scan in the assessment of severity of confirmed COVID-19 pneumonia.

Authors:  Laurent Zieleskiewicz; Thibaut Markarian; Alexandre Lopez; Chloé Taguet; Neyla Mohammedi; Mohamed Boucekine; Karine Baumstarck; Guillaume Besch; Gautier Mathon; Gary Duclos; Lionel Bouvet; Pierre Michelet; Bernard Allaouchiche; Kathia Chaumoître; Mathieu Di Bisceglie; Marc Leone
Journal:  Intensive Care Med       Date:  2020-07-29       Impact factor: 17.440

Review 4.  Laboratory characteristics of patients infected with the novel SARS-CoV-2 virus.

Authors:  Chrysanthi Skevaki; Paraskevi C Fragkou; Chongsheng Cheng; Min Xie; Harald Renz
Journal:  J Infect       Date:  2020-06-21       Impact factor: 6.072

5.  What's new in lung ultrasound during the COVID-19 pandemic.

Authors:  Giovanni Volpicelli; Alessandro Lamorte; Tomás Villén
Journal:  Intensive Care Med       Date:  2020-05-04       Impact factor: 17.440

6.  Late mesenteric ischemia after Sars-Cov-2 infection: case report.

Authors:  Vilson Sovio Oliveira de Macedo; Geterson Bezerra Moreira; Ana Cristina Fiuza de Albuquerque; Sebastião Carlos de Sousa Oliveira; Mateus Aragão Esmeraldo; Francisco Cesar Barroso Barbosa
Journal:  J Vasc Bras       Date:  2021-03-15

7.  Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study.

Authors:  Kristoffer Grundtvig Skaarup; Mats Christian Højbjerg Lassen; Caroline Espersen; Jannie Nørgaard Lind; Niklas Dyrby Johansen; Morten Sengeløv; Alia Saed Alhakak; Anne Bjerg Nielsen; Kirstine Ravnkilde; Raphael Hauser; Liv Borum Schöps; Eva Holt; Henning Bundgaard; Christian Hassager; Reza Jabbari; Jørn Carlsen; Ole Kirk; Uffe Bodtger; Matias Greve Lindholm; Lothar Wiese; Ole Peter Kristiansen; Emil Schwarz Walsted; Olav Wendelboe Nielsen; Birgitte Lindegaard; Niels Tønder; Klaus Nielsen Jeschke; Charlotte Suppli Ulrik; Morten Lamberts; Pradeesh Sivapalan; Jannik Pallisgaard; Gunnar Gislason; Kasper Iversen; Jens Ulrik Stæhr Jensen; Morten Schou; Søren Helbo Skaarup; Elke Platz; Tor Biering-Sørensen
Journal:  J Ultrasound       Date:  2021-07-02

Review 8.  Heterogeneity in reporting venous thromboembolic phenotypes in COVID-19: methodological issues and clinical implications.

Authors:  Anastasios Kollias; Konstantinos G Kyriakoulis; George S Stergiou; Konstantinos Syrigos
Journal:  Br J Haematol       Date:  2020-07-26       Impact factor: 8.615

9.  Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.

Authors:  Sonu Bhaskar; Akansha Sinha; Maciej Banach; Shikha Mittoo; Robert Weissert; Joseph S Kass; Santhosh Rajagopal; Anupama R Pai; Shelby Kutty
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

10.  Antiphospholipid Antibodies in Critically Ill Patients With COVID-19.

Authors:  Meng Xiao; Yan Zhang; Shulan Zhang; Xuzhen Qin; Peng Xia; Wei Cao; Wei Jiang; Huan Chen; Xin Ding; Hua Zhao; Hongmin Zhang; Chunyao Wang; Jing Zhao; Xuefeng Sun; Ran Tian; Wei Wu; Dong Wu; Jie Ma; Yu Chen; Dong Zhang; Jing Xie; Xiaowei Yan; Xiang Zhou; Zhengyin Liu; Jinglan Wang; Bin Du; Yan Qin; Peng Gao; Minya Lu; Xin Hou; Xian Wu; Huadong Zhu; Yingchun Xu; Wen Zhang; Taisheng Li; Fengchun Zhang; Yongqiang Zhao; Yongzhe Li; Shuyang Zhang
Journal:  Arthritis Rheumatol       Date:  2020-10-07       Impact factor: 15.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.